Q-omics provides the consensus-scored ZNF180 profile across patient tissues and cancer cell-line models. ZNF180 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF180 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ZNF180 RNA expression shows 20,668 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where ZNF180 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF180 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF180 survival associations across molecular data types. ZNF180 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF180 RNA expression–survival associations across cancer types. High ZNF180 expression shows unfavorable associations in LGG, MESO and ACC, but favorable associations in KIRC, HNSC and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF180 RNA expression.
This table summarizes ZNF180 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF180. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF180 shows lower tumor expression in THCA and higher tumor expression in BLCA, LIHC, CHOL, STAD and LUAD. The THCA box plot shows higher ZNF180 RNA expression in normal versus tumor tissue (log2 FC = −1.150, t-test p < 0.001).
This table shows molecular features associated with ZNF180 in patient tissues and cancer cell lines. In patient samples, ZNF180 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF180 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
